⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351420 | 1.00 | — | — | |
| SCHEMBL13889160 | 1.00 | — | — | |
| SCHEMBL1672698 | 1.00 | — | — | |
| SCHEMBL191998 | 1.00 | — | — | |
| SCHEMBL1983990 | 1.00 | CYP2C9 (0.39) | — | |
| SCHEMBL285299 | 1.00 | — | — | |
| SCHEMBL36515 | 1.00 | — | — | |
| SCHEMBL351728 | 1.00 | — | — | |
| Water SCHEMBL227534 | 0.94 | LMNA (0.37) | — | |
| Cyclopropane SCHEMBL483844 | 0.89 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334462-B1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | RC BIOTECHNOLOGIES INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220000889-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN INCREASING TISSULAR PERFUSION | SANIFIT THERAPEUTICS, S.A. (ES) | 2022-01-06 | — | — | US | disclosed |
| US-10772965-B2 | Covalent linkers in antibody-drug conjugates and methods of making and using the same | RC BIOTECHNOLOGIES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-20180169250-A1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | REMEGEN CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180169250-A1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | REMEGEN CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | REMEGEN CO., LTD. (CN) | 2018-03-01 | — | — | US | disclosed |
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | disclosed |
| WO-2017205384-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TARGET RNA EXPRESSION | IDERA PHARMACEUTICALS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9828601-B2 | Compositions for inhibiting checkpoint gene expression and uses thereof | IDERA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828601-B2 | Compositions for inhibiting checkpoint gene expression and uses thereof | IDERA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |